CEL-SCI Corp (STU:LSR) Stock Price, Trades & News

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.22
Equity-to-Asset	0.39
Debt-to-Equity	1.24
Debt-to-EBITDA	-0.46
Piotroski F-Score	3/9	0 1 2 3 4 5 6 7 8 9
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year EBITDA Growth Rate	38.5
	3-Year EPS without NRI Growth Rate	38
	3-Year FCF Growth Rate	31.5
	3-Year Book Growth Rate	-55.2

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.6
	Quick Ratio	0.54
	Cash Ratio	0.39

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-76.9
	Shareholder Yield %	-98.45

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	ROE %	-231.67
	ROA %	-102.35
	ROIC %	-115.66
	3-Year ROIIC %	-143.92
	ROC (Joel Greenblatt) %	-170.35
	ROCE %	-130.86
	Moat Score	2
	Tariff Resilience Score	5

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PB Ratio	1.37
	Price-to-Tangible-Book	1.39
	EV-to-EBIT	-1.17
	EV-to-EBITDA	-1.42
	EV-to-Forward-Revenue	2.79
	EV-to-FCF	-1.56
	Earnings Yield (Greenblatt) %	-85.47
	FCF Yield %	-85.85

GF Value™

STU:LSR

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with LSR. Try a 7-Day Free Trial to check it out.

CEL-SCI Corp Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

CEL-SCI Corp Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings results for 2026	2026-08-14	In 47 days
General meeting for 2026	2026-06-30	In 2 days
Second quarter earnings results for 2026	2026-05-15	5.58 (+0.00%)
First quarter earnings results for 2026	2026-02-17	5.58 (+0.00%)
Annual report for 2025	2025-12-29	5.58 (+0.00%)
LD Micro Main Event	2025-10-21 09:30	5.58 (+0.00%)
Third quarter earnings results for 2025	2025-08-14	5.58 (+0.00%)
0.0333333:1 Stock Split	2025-05-20	5.58 (-3.63%)
General meeting for 2025	2025-05-19 11:00	5.96 (-1.09%)
Second quarter earnings results for 2025	2025-05-14	6.76 (+1.35%)

Show

Entries

Press Release

	Subject	Date
	Thinking about buying stock in Livent, Bitfarms, Altus Power, Bright Minds Biosciences, or CEL-SCI Corp?	2023-07-18
	Thinking about buying stock in CEL-SCI Corp, TG Therapeutics, Missfresh, Amarin Corp, or Marathon Digital?	2022-07-13
	Thinking about buying stock in CEL-SCI Corp, TG Therapeutics, Missfresh, Amarin Corp, or Marathon Digital?	2022-07-03
	Thinking about buying stock in CEL-SCI Corp, TG Therapeutics, Missfresh, Amarin Corp, or Marathon Digital?	2022-06-23
	Thinking about buying stock in CEL-SCI Corp, TG Therapeutics, Missfresh, Amarin Corp, or Marathon Digital?	2022-06-13
	Thinking about buying stock in CEL-SCI Corp, TG Therapeutics, Missfresh, Amarin Corp, or Marathon Digital?	2022-06-03
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CEL-SCI Corporation - CVM	2021-06-29
	CEL-SCI Corporation to Present at The LD 500 Virtual Conference	2020-08-31

10/Page

Articles on CEL-SCI Corp

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.